Department of Neurological Surgery, University of Miami Miller School of Medicine, 1095 NW 14th Terrace, Miami, FL, 33136, USA.
Sylvester Comprehensive Cancer Center, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
J Neurooncol. 2021 Jun;153(2):203-210. doi: 10.1007/s11060-021-03759-x. Epub 2021 May 5.
Atypical (WHO grade II) and malignant meningiomas (WHO Grade III) are a rare subset of primary intracranial tumors. Given their relatively high recurrence rate after surgical resection and radiotherapy, there has been a recent push to explore other adjuvant treatment options for these treatment-refractory tumors. Recent advances in molecular sequencing of tumors have elucidated new pathways and drug targets which are currently being studied. This article provides a thorough overview of novel investigational therapeutics including targeted therapy, immunotherapy, and new technological modalities for atypical and malignant meningiomas.
We performed a comprehensive review of the available literature regarding preclinical and clinical evidence for emerging treatments for high grade meningiomas from 1980 to 2020 including contemporaneous clinical trials.
There is encouraging preclinical evidence regarding the efficacy of the emerging treatments discussed in this article. Several clinical trials are currently recruiting patients to translate targeted molecular therapy for meningiomas. Several clinical studies have suggested a clinical benefit of combinatorial treatment for these treatment-refractory tumors.
With numerous active clinical trials for high grade meningiomas, a meaningful improvement in the outcomes for these tumors may be on the horizon.
非典型（WHO 分级 II）和恶性脑膜瘤（WHO 分级 III）是一类罕见的原发性颅内肿瘤。鉴于它们在手术切除和放疗后复发率相对较高，最近人们一直在探索其他辅助治疗这些治疗抵抗性肿瘤的方法。肿瘤分子测序的最新进展阐明了新的途径和药物靶点，这些靶点目前正在研究中。本文全面概述了针对非典型和恶性脑膜瘤的新型研究治疗方法，包括靶向治疗、免疫治疗和新技术模式。
我们对 1980 年至 2020 年期间关于高级别脑膜瘤新兴治疗方法的现有文献进行了全面综述，包括同期临床试验。
目前有令人鼓舞的临床前证据表明，本文讨论的新兴治疗方法具有疗效。目前正在招募患者参与临床试验，以将靶向分子疗法用于脑膜瘤。几项临床研究表明，联合治疗对这些治疗抵抗性肿瘤具有临床益处。
随着针对高级别脑膜瘤的大量积极临床试验的开展，这些肿瘤的治疗结果可能会有显著改善。
